A family of 40 mammalian voltage-gated potassium (Kv) channels control membrane excitability in electrically excitable cells. The contribution of individual Kv channel types to electrophysiological signaling has been difficult to assign, as few selective inhibitors exist for individual Kv subunits. Guided by the exquisite selectivity of immune system interactions, we find potential for antibody conjugates as selective Kv inhibitors. Here, functionally benign anti-Kv channel monoclonal antibodies (mAbs) were chemically modified to facilitate photoablation of K currents. Antibodies were conjugated to porphyrin compounds that upon photostimulation inflict localized oxidative damage. Anti-Kv4.2 mAb–porphyrin conjugates facilitated photoablation of Kv4.2 currents. The degree of K current ablation was dependent on photon dose and conjugate concentration. Kv channel photoablation was selective for Kv4.2 over Kv4.3 or Kv2.1, yielding specificity not present in existing neurotoxins or other Kv channel inhibitors. We conclude that antibody–porphyrin conjugates are capable of selective photoablation of Kv currents. These findings demonstrate that subtype-specific mAbs that in themselves do not modulate ion channel function are capable of delivering functional payloads to specific ion channel targets.
Voltage-gated potassium (Kv) channels play diverse roles including controlling the repolarization phase of action potentials in electrically excitable cells throughout the brain and body. In mammals, Kv channels arise from a family of 40 genes encoding pore-forming subunits (Gutman et al., 2005). This genetic diversity is greater than any other family of ion channels, and individual cells express an array of different Kv types. Each channel type has a distinct subcellular distribution and functional properties to make a unique contribution to electrical signaling (Vacher et al., 2008). Selectively inhibiting Kv subtypes is a promising method of tuning electrical excitability for research and clinical purposes, yet has been difficult in practice.
The diversity of Kv channels poses a challenge to biomedical science. The contribution to electrical signaling of any individual channel type is difficult to conclusively demonstrate. Hence, the precise physiological function of most Kv subunits remains unknown. For most Kv subunits, drugs of great selectivity have not yet been discovered. In the rare cases where selective Kv inhibitors have been found, they have proven indispensable in identifying channel functions. For example, extensive efforts to develop pharmacology selective for Kv channels in human T lymphocytes (DeCoursey et al., 1984; Grissmer et al., 1990; Lin et al., 1993) led to the identification of the pivotal role of Kv1.3 in immune activation, and the channel is now the target of several drugs in clinical trials (Beeton et al., 2006; Tarcha et al., 2012). For most Kv channels, researchers rely on a patchwork pharmacology insufficient to conclusively identify the function of specific channel types. Because of the inadequacy of subtype-selective Kv drugs, the limiting step in developing Kv therapies remains the process of identifying a specific channel type as a target for drug development, or “target validation” (Kaczorowski et al., 2008; Rhodes and Trimmer, 2008). Ideally, to identify the physiological roles of Kv channels, a selective drug would be available for every Kv type.
Selective antibodies have been developed against most Kv subunits (Vacher et al., 2008). However, generation of antibodies that inhibit ionic current has proven difficult. There are several publications describing inhibitory antibodies that target Kv subunits (Zhou et al., 1998; Murakoshi and Trimmer, 1999; Jiang et al., 2003; Xu et al., 2006; Gómez-Varela et al., 2007; Yang et al., 2012), but none of these antibodies has yet emerged with the qualities required for widespread use (Dallas et al., 2010). What would be most useful to researchers are mAbs against extracellular epitopes that robustly modulate function of mammalian Kv channels.
We have generated several mAbs that bind epitopes on the external face of Kv channels. These exhibit clear specificity for Kv subtypes, including Kv1.1 (Tiffany et al., 2000), Kv2.1 (Lim et al., 2000), and Kv4.2 (Shibata et al., 2003). None of these mAbs has been found to inhibit currents. Our objective is to harness the exquisite selectivity of these mAbs to selectively modulate Kv function. By attaching inhibitory moieties to subtype-selective mAbs, we aim to find a solution to the problematic scarcity of selective Kv inhibitors that can be applied to all subtypes.
In this communication, we report a means of imbuing benign anti-Kv mAbs with inhibitory potency. Our strategy for targeted inhibition of Kv channels was to label antibodies with chromophores that induce oxidative damage to the target protein upon photostimulation. Such strategies have proven useful to permanently inhibit proteins (Beck et al., 2002; Lee et al., 2008). Related strategies involving genetically targeted photosensitizers have also proven to be a viable means of inhibiting membrane proteins including ion channels and aquaporins (Tour et al., 2003; Baumgart et al., 2012). In all of these strategies, photostimulation of certain chromophores leads to the local generation of reactive oxygen species. The lifetime of the reactive species determines its diffusional distance and hence a radius of localized oxidative damage. One extensively used species is singlet oxygen, which has an ∼40-Å half-maximal radius of oxidative damage (Beck et al., 2002; Vegh et al., 2011). Oxidative damage mediated by singlet oxygen has proven capable of ablating the function of a wide range of protein targets but also results in varying degrees of collateral damage to other cell components (Guo et al., 2006). As the use of efficient reactive oxygen–generating species may help minimize unintended damage, we sought to find chromophores with optimal properties. In this work, we test the capacity of porphyrin conjugates to mediate photoablation of ionic currents. Porphyrins are among the most efficient photo-induced generators of singlet oxygen known. For example, 5,10,15,20-tetrakis(1-methylpyridinium-4-yl)porphine, which is closely related to the photosensitizer, 1, used here (Fig. 2 A), has a singlet oxygen quantum yield in water of 0.74 (Verlhac et al., 1984). This is far higher than the quantum yield of 0.03–0.06 reported for fluorescein (Wilkinson et al., 1993), which is classically used for targeted photoablation of protein function (Redmond and Gamlin, 1999; Smith et al., 2011). Additionally, as with most porphyrins, our photosensitizer, 1, has a greater maximal extinction coefficient, ε425 nm = 220,000 M−1 cm−1 (Tomé et al., 2004), than fluorescein, ε490 nm = 76,900 M−1 cm−1 (Sjoback et al., 1998). Because of their efficient photostimulated generation of reactive oxygen, porphyrins are used clinically in photodynamic therapy for cancer treatment (Bonnett, 1995; Agostinis et al., 2011). We have previously used virus capsids loaded with porphyrins to target cancer cells (Stephanopoulos et al., 2010), and there are reports of mAbs targeting porphyrins to cancer cells (Alonso et al., 2010; Palumbo et al., 2011). Here, we target porphyrin photosensitizers with subtype-specific mAbs. We find that currents from Kv channels can be selectively ablated by photostimulation of antibody-conjugated porphyrins.
MATERIALS AND METHODS
To target photoinhibitors to Kv channels, an extensively validated, subtype-selective anti-Kv mAb was chosen. The IgG1 clone K57/1 (Shibata et al., 2003) was found to be selective for mammalian Kv4.2 channels (Rhodes et al., 2004; Menegola and Trimmer, 2006), has been used for studies by multiple research groups (Burkhalter et al., 2006; Gardoni et al., 2007; Kim et al., 2007; Amarillo et al., 2008; Hammond et al., 2008), and is publicly available from the UC Davis/National Institutes of Health NeuroMab facility. The K57/1 mAb was generated against a synthetic peptide, “Kv4.2e,” that mimicked amino acids of the external loop between the S1 and S2 segment of the human Kv4.2 subunit (Fig. 1 A). The S1–S2 linker is the longest and most variable external region of Kv proteins and, as such, is an attractive target for generating subtype-specific externally acting antibodies. The Kv4.2e sequence is identical in human, rat, mouse, and other mammalian Kv4.2 orthologues. The K57/1 antibody is highly specific for Kv4.2 over its closely related family members Kv4.1 and Kv4.3 (Rhodes et al., 2004). K57/1 exhibits robust binding in immunohistochemical staining of the intact brains and in immunoblot analyses of denatured protein samples prepared from wild-type mice did not exhibit detectable signals in Kv4.2 knockout mice (Fig. 2, B and C) (Menegola and Trimmer, 2006). To date, all anti-Kv channel S1–S2 linker antibodies we have tested, including the K57/1 mAb, have proven ineffectual as inhibitors of their targeted Kv channels (Fig. 1 D).
All animals were cared for and euthanized in accordance with institutional animal use protocols. Rat and mouse brain membranes were prepared as described previously (Shi et al., 1994). Mouse brain membranes were prepared from brains of Kv4.2 knockout mice (Guo et al., 2005) and wild-type littermates. In brief, brains from adult rats and mice were homogenized in 5 mM sodium phosphate buffer (PB), pH 7.4, containing 320 mM sucrose and 100 mM NaF. The homogenate was centrifuged at 800 g for 10 min to remove nuclei and unbroken tissues, and then centrifuged at 100,000 g to prepare a membrane fraction. Membranes were diluted with the sample buffer for SDS-PAGE. Molecular weight standards were Amersham Rainbow Markers (RPN800). Proteins were separated by SDS-PAGE on 7.5% gels, transferred to nitrocellulose membranes, and immunoblotted with anti-Kv4.2 K57/1 or anti-Kv2.1 K89/41 (Antonucci et al., 2001) mouse mAb tissue culture supernatants at 1:2. The blots were incubated with horseradish peroxidase–conjugated secondary antibodies (MP Biomedicals), followed by enhanced chemiluminescence reagent (PerkinElmer). Immunoreactive bands were visualized by exposing the blot to x-ray film.
Immunofluorescence staining of brain sections
Mice were deeply anesthetized with sodium pentobarbital (60 mg/kg, intraperitoneally) and perfused through the ascending aorta with 20 ml of 0.9% saline, followed by 80 ml of fixative containing 4% formaldehyde, prepared from freshly depolymerized paraformaldehyde, in 0.1 M PB. The brains were removed, cryoprotected for 18–48 h in 20% sucrose, frozen in a bed of pulverized dry ice, and then cut into 40-µm sagittal sections on a sliding microtome (Michrom HM 450; Richard-Allan Scientific) equipped with a freezing stage (BFS-30TC and PTU-3; Physitemp). Sections were collected in 0.1 M PB and processed immediately for immunohistochemistry as described below.
For immunohistochemistry, sections were washed four times for 5 min each in ice cold 0.1 M PB and blocked for 1 h at 4°C in vehicle (10% goat serum, 0.1 M PB, and 0.3% Triton X-100). Sections were incubated overnight at 4°C in vehicle containing anti-Kv4.2 mouse mAb K57/1 and anti-Kv2.1 affinity-purified rabbit polyclonal antibody KC (Trimmer, 1991). Sections were washed four times for 5 min each in vehicle and incubated for 1 h in vehicle containing affinity-purified, species-specific goat secondary antibodies conjugated to Alexa Fluors (Life Technologies). Sections were then washed again for 5 min each in vehicle, 0.1 M PB, and 0.05 M PB, and mounted on gelatin-coated slides, dried, and coverslipped using mounting medium (ProLong Gold; Life Technologies).
Fluorescence images were taken using the same exposure time for each set of samples to directly compare the signal intensity. Images were acquired with a charge-coupled device camera installed on an Axiovert 200-M microscope with a 20×, 0.8 numerical aperture lens, and an ApoTome coupled to Axiovision software (Carl Zeiss). Images were exported from Axiovision as TIFF or JPEG files and imported into Photoshop (Adobe).
Porphyrin synthesis and antibody conjugation
To imbue antibodies with photoinhibitory functionality, water-soluble porphyrin compounds were synthesized and functionalized for conjugation to proteins. The porphyrin ring is aromatic and hydrophobic, with sparing water solubility. The porphyrins used in this work were chemically altered to increase their hydrophilicity by appending charged moieties to three of the four aryl groups projecting from the porphyrin ring. Positive charges were introduced by using methylated pyridine derivatives, and negative charges were introduced by attaching sulfonate groups to the aryl rings (Fig. 2 A). The fourth aryl group projecting from the porphyrin core was engineered for linkage to antibodies. Porphyrins were synthesized for three conjugation strategies: porphyrin 1 for N-hydroxysuccinimide–mediated addition to mAb primary amine groups (e.g., lysines); porphyrin 2 for isothiocyanate-mediated addition to primary amine groups; and porphyrin 3 for the conjugation of aminooxy groups to aldehydes/ketones introduced into the antibody amino termini using a pyridoxal-6-phosphate–mediated transamination reaction (Gilmore et al., 2006; Scheck and Francis, 2007). Water-soluble porphyrins were reacted with K57/1 antibody (Fig. 2 B), and these antibody–porphyrin conjugates tested for photoinhibitory activity against Kv channels.
Cationic porphyrin-NHS ester 1 (Fig. 2 A) was prepared according to a published procedure (Tomé et al., 2004). The final product was stored at −20°C as a 10-mM solution in DMSO. Anti-Kv4.2 antibody porphyrin 1 conjugate (αKv4.2•1) was prepared as follows: anti-Kv4.2 mAb K57/1 (Shibata et al., 2003) was initially purified from ascites fluid, as described previously (Trimmer et al., 1985). The antibody was further purified by elution from protein G sepharose (GE Healthcare), with 0.5 M acetic acid, neutralization with 0.6 volumes of 1 M sodium phosphate, pH 8.0, concentration in a centrifugal filter unit (30 K Amicon-4; EMD Millipore), and dialysis against 100 mM sodium phosphate, pH 8. In an opaque black polypropylene tube, with precautions taken to minimize light exposure, purified mAb (7 µM) was mixed with 16 equivalents of cationic porphyrin-NHS in DMSO, for 10% final DMSO concentration. The reaction vessel was purged with argon, and the reaction allowed to proceed for 3 h at 4°C, before termination by application to a desalting resin (Zeba; Thermo Fisher Scientific) preequilibrated with 150 mM NaCl and 10 mM PB, pH 7.3. The degree of antibody modification was approximately two porphyrins per antibody molecule, as determined from absorbance readings (Fig. 2 C) on wavelength-scanning spectrophotometer (Cary 50 Scan; Varian) using extinction coefficients (M−1 cm−1) porphyrin 1, ε280 nm = 10,000 and ε425 nm = 220,000, and IgG, ε280 nm = 210,000. This mAb–porphyrin conjugate, αKv4.2•1, was protected from light and stored with 1% BSA (03117332001; Roche) and 10 mM sodium azide at 4°C until use.
Anionic porphyrin isothiocyanate 2 (Fig. 2 A) was synthesized from 5-(4-aminophenyl)-10,15,20-tris(4-sulfonatophenyl)porphyrin, tris(n-tetrabutylamminonium) salt, according to published procedures (Endo et al., 2007; Stephanopoulos et al., 2009) as follows: the starting porphyrin (16 mg, 0.01 mmol) was dissolved in 4 ml anhydrous dichloromethane (DCM). To this solution was added 1,1′-thiocarbonyldi-2(1H)-pyridone (5 mg, 0.02 mmol) in 1 ml DCM. The reaction was stirred at room temperature and reacted to completion in 2 h, as monitored by matrix-assisted laser desorption/ionization–time of flight (MALDI-TOF) mass spectroscopy. The solvent was removed under reduced pressure. The crude mixture was dissolved in DCM and product purified by silica gel chromatography, first using 10% methanol in DCM to elute unreacted pyridone, and then 50% methanol in DCM to elute the porphyrin. Product purity was verified by MALDI-TOF mass spectrometry. Solvent was removed under reduced pressure, and the porphyrin was stored at −20°C as a 20-mM solution in DMSO. To the purified K57/1 antibody (7 µM) in 0.5 M sodium bicarbonate, pH 9.2, 16 equivalents of anionic porphyrin 2 in DMSO were added, for a 10% final concentration of DMSO. The reaction vessel was purged with argon, and reaction was allowed to proceed for 1 h on ice. This conjugate, αKv4.2•2, was prepared as described above for αKv4.2•1.
Anionic porphyrin alkoxyamine 3 (Fig. 2 A) was prepared as described previously (Stephanopoulos et al., 2009) and was stored in DMSO until use. For conjugation to the antibody, it was first necessary to generate a ketone at the amino terminus of the antibody using a pyridoxal 5′-phosphate–based transamination reaction, as described previously (Gilmore et al., 2006). In brief, the K57/1 antibody (7 µM) in 50 mM phosphate buffer, pH 6.5, was exposed to 10 mM pyridoxal 5′-phosphate and allowed to react overnight at room temperature. The reaction was terminated by application to a desalting resin (Zeba; Thermo Fisher Scientific) prequilibrated with 150 mM NaCl and 10 mM PB, pH 7.3. To this transaminated antibody, 10 equivalents of anionic porphyrin 3 in DMSO were added, for a 10% final concentration of DMSO. The reaction vessel was purged with argon, and reaction was allowed to proceed overnight at room temperature. This conjugate, αKv4.2•3, was prepared as described above for αKv4.2•1.
The anti-Kv4.2 mAb K57/1 was generated against a synthetic peptide, Kv4.2e, CGSSPGHIKELPSGERY, in which the second cysteine from the corresponding Kv4.2 sequence (Fig. 1 A) was changed to serine for chemistry considerations (Shibata et al., 2003). The Kv4.2e peptide was conjugated to BSA by its amino-terminal cysteine and prepared as follows: a 0.5-ml aliquot of 10 mg/ml BSA dialyzed against 50 mM sodium phosphate, pH 6.0, was incubated with 800 µg sulfo-MBS (Thermo Fisher Scientific) on a tube rotator at room temp for 30 min. The product was passed through a G-50 column (Sephadex) equilibrated in 50 mM sodium phosphate, pH 6.0, to remove unconjugated sulfo-MBS. The peak 1-ml BSA fraction was added to 5 mg synthetic peptide dissolved in 0.5 ml of 1 mM EDTA and 20 mM sodium phosphate, pH 7.2, and rotated overnight at room temperature; aliquots were stored at −20°C until use.
96-well microtiter plates (655081; Greiner) were coated with 50 µl of 50 µg/ml Kv4.2e-BSA conjugate or a BSA control in 10 mM sodium azide overnight at 4°C. After a 45-min block with blotto (20 mM Tris HCl, pH 8, 150 mM NaCl, 4% nonfat dry milk, and 0.1% Tween 20) at room temperature, 50-µl primary antibody dilutions in blotto ± blocking peptide were added to wells and rocked gently for 45 min at room temperature. The 1° antibody solution was removed, and wells were washed with blotto three times at 5-min intervals, followed by a 45-min incubation with goat anti–mouse heavy and light chain–specific 2° antibody–horseradish peroxidase conjugate (KPL 474–1806) diluted at 1:5,000 in blotto. Wells were then washed three times at 5-min intervals with PBS (150 mM NaCl and 10 mM sodium phosphate, pH 7) and developed in 50 µl 3,3′,5,5′-tetramethylbenzidine solution (34028; Thermo Fisher Scientific) for 5 min before stop with 50 µl of 2 M sulfuric acid. Absorbance at 450 nm was quantified.
CHO-K1 cells were maintained in Ham’s F12 media (Gibco) containing 10% FBS (Hyclone) at 37°C in a 5% CO2 atmosphere. A stable Kv4.2 CHO-K1 cell line was generated with Kv4.2ΔN2-31 (Shibata et al., 2003) subcloned into a tetracycline-inducible expression system (TREx CHO; Life Technologies). 2 d after transfection (Nucleofector; Lonza), 10 µg/ml blasticidin and 250 µg/ml zeocin were added to culture media. To induce channel expression for electrophysiological recording, 1 µg/ml tetracycline was added to the maintenance media for 10–20 h to induce a desirable amount of channel expression. The Kv2.1 TREx CHO cell line (Trapani and Korn, 2003) was cultured similarly and required 1 µg/ml tetracycline for 1–2 h for channel expression. Kv4.3/RGB4 (Rhodes et al., 2004) was transfected similarly with an EGFP/pMax vector (Lonza), and currents were recorded 40–70 h after transfection. Kv4.2 HEK cells expressed a Kv4.2-GFP construct (Shibata et al., 2003), stably transfected into HEK293 cells, and were maintained in DMEM media containing 10% FBS and 500 µg/ml G418 (Life Technologies). For electrical recording, cells were harvested by scraping in a PBS with 1 mM EDTA (Versene; Life Technologies), pelleted at 1,000 g for 2 min, resuspended in CHO-SFMII media (Life Technologies) supplemented with 25 mM HEPES, pH 7.3, and rolled in a polypropylene tube at room temperature until use.
Whole cell voltage-clamp recordings were used to measure currents from Kv channels. Aliquots of cell suspension were added to a recording chamber and rinsed with external solution 5 or more minutes before recording. The external (bath) solution contained (mM): 20 HEPES, 10 KOH, 117 NaCl, 2 CaCl2, 2 MgCl2, and 0.1 MgEDTA, adjusted to pH 7.3 with HCl. The internal (pipette) solution contained (mM): 50 KF, 70 KCl, 35 KOH, 5 EGTA, and 50 HEPES, adjusted to pH 7.3 with HCl. A calculated liquid junction potential of 9.6 mV was corrected. Pipette tip resistances with these solutions were <3 MΩ. Recordings were done at room temperature (22–24°C). Voltage clamp was achieved with an amplifier run by Patchmaster software (EPC-10; HEKA). The holding potential was −100 mV. Series resistance compensation was used when needed to constrain voltage error to <10 mV. When indicated, capacitance and ohmic leak were subtracted using a P/5 protocol. Recordings were low-pass filtered at 5 kHz and digitized at 100 kHz. All recordings were made after the addition of 0.1% BSA. Antibody–porphyrin conjugates were applied in external solution with 0.1% BSA at least 100 s before illumination, with light exposure kept to a minimum until illumination start. Antibodies were added by pipetting 100 µl of a 2× concentration into a recording chamber (R-24N; Warner) containing ∼100 µl of solution.
Illumination for photoablation was administered by manually shuttering the epifluorescence input into a microscope (Axiovert 100; Carl Zeiss). Light source was a 100-W mercury arc lamp filtered by a 395–440-nm excitation filter (Zeiss filter set at 05). Unless noted otherwise, a 10× objective (1020–863; Carl Zeiss) was used for illumination. The total illumination output of the objective was 8–12 mW, as measured by a photodiode (S130VC; Thorlabs) calibrated at 425 nm. lllumination was adjusted by eye to be homogeneous across the field of view, with the patch-clamped cell centered in the field of view and plane of focus on the greatest diameter of the cell membrane.
Analysis and graphing were performed with IgorPro software (WaveMetrics), which performs nonlinear least-squares fits using a Levenberg–Marquardt algorithm. K current photoablation was fit with an exponential decay function:(1)where time is the time elapsed since onset of illumination, rate is the photoablation rate, A is amplitude, and base is current remaining at time = ∞. The figure legends report rate ± SD and f ± SD, where f is the fraction of current ablated when current = base. When rate was so slow as to be poorly constrained (<0.01 s−1), base was constrained to 0. This constraint did not alter the significance of any statistical comparisons. Significance was determined by rank using the nonparametric Mann–Whitney U test. Asterisks indicate P < 0.05. In the figures, electrophysiological current traces were digitally smoothed with a 2-kHz Gaussian filter. Error bars indicate mean ± SEM.
Antibody–porphyrin conjugates facilitate targeted K current photoablation
Antibody–porphyrin conjugates were added to the external solution of patch-clamped cells heterologously expressing Kv channels. After a brief incubation period to allow antibodies to bind channel targets, photostimulation of the highest extinction coefficient absorption (Soret) band of the anti-Kv4.2 mAb–porphyrin 1 conjugate, αKv4.2•1 (Fig. 2 C), resulted in progressive inhibition of Kv4.2 current with photon dose (Fig. 3, A and B). This irreversible photoablation is consistent with oxidative damage to channels from diffusible reactive oxygen species generated by photostimulated porphyrin, such as singlet oxygen, as schematized (Fig. 2 D). Photoablation was also apparent after washout of mAb conjugate (Fig. 3 C), consistent with the conjugate channel complex having a slow dissociation rate from the targeted channels.
The αKv4.2•1 porphyrin–mAb conjugates allowed selective photoablation of the targeted Kv channels. There was little photoablation of Kv4.3 or Kv2.1 in response to photon doses that eliminated Kv4.2 currents, suggesting that antibody targeting could direct the photoablation effect (Fig. 4). The effect of increasing photon dose was quantified as a photoablation rate, corresponding to the inverse time constant of current loss under our illumination conditions (Fig. 4 E). With prolonged illumination, current was gradually lost from the off-target Kv2.1 and Kv4.3 channels. This side effect indicated that although the anti-Kv antibody could direct photoablation to channels of interest, collateral damage also occurred. Alternate porphyrin chemistries were not as successful at enabling targeted photoablation. The mAb–porphyrin conjugates of the two anionic porphyrins synthesized (2 and 3) did not selectively ablate currents from the targeted Kv4.2 channel. Under more intense illumination, high photon doses yielded nonselective photoablation against all channels tested (Fig. 5). This suggests that the ability of the K57/1 antibody to recognize its epitope is compromised by attachment of the anionic conjugates. It is not clear why the anionic conjugates were not targeted as effectively as their cationic counterpart, αKv4.2•1. The weaker, nonselective effects of αKv4.2• and αKv4.2•3, together with the off-target effects of αKv4.2•1 on Kv2.1 and Kv4.3, demonstrate that a mechanism beyond antibody–epitope binding can also lead to photoablation. Yet, with this technique, nonselective side effects were dwarfed by selective antibody-guided photoablation of Kv currents.
To further test the mechanism of Kv subtype targeting, we probed the selectivity of mAb conjugates with a blocking peptide. Preincubation with soluble Kv4.2e peptide prevented binding of 5 nM anti-Kv4.2 mAb to its epitope, with an IC50 of 7 nM (Fig. 6, A and B). When mAb conjugates were preblocked with saturating concentrations of this soluble epitope, photoablation by the cationic porphyrin–antibody conjugate was reduced (Fig. 6 C). The αKv4.2•1 photoablation of Kv4.2 currents was not completely blocked by the antigenic peptide, with the residual photoablation refractory to increased concentrations of peptide blocker. The block of photoablation by peptide is consistent with our other findings, where a degree of off-target effects accompany antibody-guided photoablation.
Targeted photoablation reduces K current magnitude without altering gating
The details of mAb-guided photoablation were investigated to better understand how K current elimination occurs. The degree of photoablation was found to be dependent on the concentration of K57/1 antibody–porphyrin conjugate applied. Increased concentration resulted in photoablation of a greater fraction of K current (Fig. 7 A). During photostimulation, the rate of Kv4.2 current decay did not reveal a consistent difference between the conjugate concentrations tested (Fig. 7 B). The dynamics of remaining current elicited from cells after partial photoablation was similar to control. The sigmoid activation kinetics of Kv4.2 were similar to currents elicited before illumination, as were decaying tail currents from deactivation at negative voltages (Fig. 8 A), and inactivation (Fig. 3 A). The normal behavior of current remaining after photoablation contrasts with the progressive alteration of the channel gating machinery, as is seen with cyclic nucleotide–gated channels (Middendorf and Aldrich, 2000; Middendorf et al., 2000). The extent of Kv photoablation could be halted at a given level by the termination of illumination (Fig. 8 B), indicating that the physical processes leading to irreversible current loss are rapid events, rather than the triggering of a slow decay process.
Photoablation inflicts collateral damage
The technique of porphyrin-mediated photoinhibition presents some technical difficulties that can complicate its application in the laboratory. Among these limitations are an endogenous photosensitivity of Kv channel currents and leak currents in cell membranes that are sometimes induced by photostimulation of porphyrin–mAb conjugates.
Limited Kv current photoablation was sometimes observed in the absence of porphyrins. Although photosensitivity of channels to the 420-nm illumination was usually not apparent without porphyrins added (Fig. 7 A), in certain cells there was a notable response to illumination, a particularly striking example of which is shown in Fig. 8 C. Although the endogenous photosensitivity complicates interpretation, it never approached the rate of photoablation observed with antibody–porphyrin conjugates (Fig. 7 B). It is not clear what endogenous chromophore may be mediating the response to illumination. In attempts to prevent background photoablation, a panel of reducing agents was added to the patch pipette, including 10 mM of reduced glutathione, 25 mM potassium ascorbate, 500 U/ml superoxide dismutase, 50 mM dithiothreitol, and 40 µM trolox C. These reducing agents were not effective at preventing background photoablation (unpublished data).
Another complicating facet of applying antibody–porphyrin-guided photoablation to patch-clamp studies was a variable level of photostimulated leak current that sometimes occurred. Leak currents occurred frequently, but inconsistently, after photostimulation of cells exposed to antibody–porphyrin conjugates. An example of the membrane leak sometimes accompanying photoablation is shown in Fig. 8 (D and E). Photostimulation inconsistently triggered an increased leakiness of the membrane that could further develop after cessation of illumination. A previous study using reactive oxygen–mediated photoablation of membrane proteins reported collateral damage to other cellular proteins (Guo et al., 2006), and the leak currents appearing in our experiments appear to be a manifestation of some form of collateral oxidative damage.
We have found that antibody-guided, porphyrin-mediated photoablation can select among Kv4 subtypes. This method of targeting channels yielded better specificity for Kv4.2 over Kv4.3 and Kv2.1 than any inhibitor we are aware of. Ablation of currents with conjugates of benign antibodies offers a new route toward pinpointing the molecular identity of endogenous channels underlying ionic current.
Porphyrin-conjugated derivatives of an anti-Kv mAb imbued photoablation specificity against a targeted Kv channel. This method also inflicted collateral damage against other channels and likely the cell membrane itself. The mechanism of collateral damage is unclear. We speculate that it is caused by an innate affinity of porphyrins for cell membranes, resulting in nonspecific adsorption of porphyrin–mAb conjugates to cell surfaces. Upon photostimulation, singlet oxygen from the adsorbed conjugates could harm other channels, damage the membrane to increase electrical leak, and inflict additional undetected forms of oxidative damage to the cell. This collateral damage is consistent with side effects noted by Guo et al. (2006) when photostimulating fluorescein conjugates on cell surfaces. Nonetheless, porphyrin conjugates have been useful in demonstrating the concept of antibody-guided Kv inhibition. This strategy could be improved upon by conjugating less technically problematic inhibitors.
We are currently working to conjugate promiscuous inhibitors of Kv channels to anti-Kv mAbs while retaining the function of both components. The ability of benign antibodies to deliver inhibitory payloads to Kv channels is clear. Antibody-guided channel modulators could provide the experimental tools needed to reveal the specific physiological roles each Kv subunit is fulfilling in the body.
We are grateful to Dr. Leah Witus for inspiring this project. We thank Jordy Hsiao, Olga Lenkov, and Kenneth Eum for technical assistance, as well as Dr. Milena Menegola for brain immunohistochemistry.
This research was supported by National Institutes of Health National Institute of Neurological Disorders and Stroke grant R01NS042225, supplement R01NS042225-09S1 (to J.S. Trimmer), and American Heart Association grant 10SDG4220047 (to J.T. Sack).
Author Contributions: J.T. Sack, N. Stephanopoulos, and J.S. Trimmer generated reagents; J.T. Sack, D.C. Austin, and J.S. Trimmer performed experiments; J.T. Sack and D.C. Austin analyzed data; J.T. Sack, J.S. Trimmer, N. Stephanopoulos, and M.B. Francis wrote the manuscript.
Kenton J Swartz served as editor.
- Abbreviations used in this paper:
- voltage-gated potassium
- sodium phosphate buffer
- Submitted: 8 May 2013
- Accepted: 19 July 2013
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).